StockWatch
·

NOVAVAX INC Q3 FY26 Results

NVAXQ3 FY26 Results
Filing
MetricValue ($ M)Q2 FY26Q3 FY25
Revenue68.3020.5%3.0%
Total Income68.3020.5%3.0%
Expenditure99.5810.8%59.9%
PBT-29.6542.6%85.4%
Net Profit-31.3841.2%84.5%
OPM-45.80%51.04pp
NPM-45.94%48.22pp
EPS-0.1940.6%84.8%
View full financials

Novavax Reports Q3 2026 Financial Results and Operational Highlights

05 Nov 2026 · 5 Nov, 6:41 pm

Summary

Novavax reported third quarter 2026 total revenue of $68 million, a 3% decrease year-over-year. Product sales saw a substantial 91% increase to $26 million, while licensing, royalties, and other revenue declined by 25%. The company significantly reduced its net loss to $31 million from $202 million in the prior year's quarter. Management raised full-year 2026 guidance for Non-GAAP Adjusted Total Revenue and improved expense guidance, highlighting the $125 million milestone payment received from Sanofi's Phase 3 trial initiation.

Key Highlights

  1. 1

    Novavax reported total revenue of $68 million for the third quarter of 2026, a 3% decrease compared to $70 million in the same period in 2025.

  2. 2

    Product sales increased by 91% to $26 million in Q3 2026 compared to $13 million in Q3 2025, driven by Nuvaxovid supply sales.

  3. 3

    Licensing, royalties and other revenue decreased by 25% to $43 million in Q3 2026, primarily due to a reduction in R&D reimbursement revenue.

  4. 4

    The company raised its full-year 2026 Non-GAAP Adjusted Total Revenue guidance by $145 million to $400 million at the mid-point.

  5. 5

    Novavax improved its GAAP Combined R&D and SG&A expense guidance by $5 million at the mid-point for the full year 2026.

  6. 6

    A $125 million milestone was earned in October 2026 upon Sanofi's launch of a Phase 3 influenza-COVID-19 combination vaccine trial in Europe.

  7. 7

    The net loss for the third quarter of 2026 was $31 million, a significant improvement from a net loss of $202 million in the same period in 2025.

Management Comments

J

John C. Jacobs

This quarter, we continued to execute across all three pillars of our strategy. Our partner Sanofi initiated their Phase 3 influenza-COVID-19 combination vaccine trial vaccine trial in Europe, triggering a $125 million milestone payment. Our focused R&D efforts are building a growing body of data on what our technology can do in infectious disease, advancing our C. difficile candidate towards the clinic and exploring oncology as a potential new area of application. And we have been doing this while continuing to reduce expenses and operate with financial discipline. Over time, we believe this strategy can build a robust and profitable Novavax, with multiple partners and products, diversified revenue streams and a meaningful impact on global health.

Informational and educational content only. Not investment advice.